Oral ibuprofen versus placebo in closure of patent ductus arteriosus in preterm neonates, a randomized control trial
Journal of Neonatal-Perinatal Medicine · 2024
DOI: 10.1177/19345798241302264 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Neonatal-Perinatal Medicine, 2024. Verfasst von Dalia Fathi El Sherif und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Ductus Arteriosus, Patent, Ibuprofen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
A consensus on treatment of patent ductus arteriosus (PDA) in preterm neonates remains elusive. Conservative management has recently gained popularity due to medical treatment lacking the evidence of benefit in terms of mortality and morbidity.
Objective
This study compares the efficacy of the standard dose of oral Ibuprofen versus placebo in the closure of PDA in preterm neonates ≤34 weeks gestation.
Methods
Eighty enrolled preterm neonates with a hemodynamically significant PDA (hsPDA) were randomized to either receive an early 3-day course oral ibuprofen or placebo (1:1). The open-label option and an extended oral ibuprofen therapy were offered if there were concerns over patient’s clinical condition being attributed to PDA and only if showing evidence of systemic and/or pulmonary hyperperfusion.
Results
No significant difference in PDA closure between both groups (62.5% vs 65% in Ibuprofen & placebo group respectively, p = .816). No significant difference was observed between groups in mortality ( p = 1), Bronchopulmonary dysplasia (BPD) ( p = 1), or necrotizing enterocolitis (NEC) (0.5). Placebo group required a longer duration of inotropic support (median of 10 vs 7.5 days in Ibuprofen group, p = .013) and were prescribed more diuretic therapy (27 vs 18 in Ibuprofen group, p = .043).
Conclusion
The standard dose of oral ibuprofen was comparable to placebo in early treatment of hsPDA in preterm neonates less than 34 weeks in terms of effect on ductal closure after one course of treatment, incidence of mortality, and morbidities like NEC, and BPD. Failure of ductal closure itself was associated in both groups with increased mortality, failure to reach full feeds, and more use of vasopressors and inotropes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
ORCID-Profile: Ghada Ahmad Saleh, Nada Hussein Youssef
Zitieren
APA
El Sherif, D. F., El Raggal, N. M., Nasef, M. W., Saleh, G. A., Youssef, N. H., & Metwally, M. H. (2024). Oral ibuprofen versus placebo in closure of patent ductus arteriosus in preterm neonates, a randomized control trial. Journal of Neonatal-Perinatal Medicine. https://doi.org/10.1177/19345798241302264
Vancouver
El Sherif DF, El Raggal NM, Nasef MW, Saleh GA, Youssef NH, Metwally MH. Oral ibuprofen versus placebo in closure of patent ductus arteriosus in preterm neonates, a randomized control trial. Journal of Neonatal-Perinatal Medicine. 2024. doi:10.1177/19345798241302264
BibTeX
@article{ElSherif2024,
author = {El Sherif, Dalia Fathi and El Raggal, Nehal Mohamed and Nasef, Marwa Waheed and Saleh, Ghada Ahmad and Youssef, Nada Hussein and Metwally, Mohamed Hussein},
title = {Oral ibuprofen versus placebo in closure of patent ductus arteriosus in preterm neonates, a randomized control trial},
journal = {Journal of Neonatal-Perinatal Medicine},
year = {2024},
doi = {10.1177/19345798241302264}
}
EUVIMED